Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.
<h4>Background</h4>Currently, quadruple therapy is unanimously recommended as the current first-line treatment option for Helicobacter pylori (H. Pylori) eradication. However, the drug composition of quadruple therapy is very complex, and the efficacy and safety between them is not clear...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0318937 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850190120424046592 |
|---|---|
| author | Jiali Wei Zehao Zheng Xin Wang Boyi Jia Mingyao Sun Jiayi Wang Qin Wan Mei Han Yue Qiu |
| author_facet | Jiali Wei Zehao Zheng Xin Wang Boyi Jia Mingyao Sun Jiayi Wang Qin Wan Mei Han Yue Qiu |
| author_sort | Jiali Wei |
| collection | DOAJ |
| description | <h4>Background</h4>Currently, quadruple therapy is unanimously recommended as the current first-line treatment option for Helicobacter pylori (H. Pylori) eradication. However, the drug composition of quadruple therapy is very complex, and the efficacy and safety between them is not clear.<h4>Aims</h4>To compare the efficacy and safety of H. Pylori eradication regimens, which were recommended by the Fifth Consensus of China, by network meta-analysis.<h4>Methods</h4>Literature databases were used to retrieve clinical randomized controlled trials of H. Pylori eradication. Network meta-analysis was performed using BUGSnet and meta package of R software, using OR values as effect size, and SUCRA was used to rank the efficacy of interventions under each outcome.<h4>Results</h4>A total of 55 studies and 130 arms were included. The NMA analysis found that the top regimen in term of eradication rate outcome was: Rabeprazole + Bismuth + Furazolidone + Tetracycline (SUCRA, 97.5). In terms of safety outcomes: Lansoprazole + Bismuth + Amoxycillin + Clarithromycin (SUCRA, 91.97).<h4>Conclusions</h4>The bismuth quadruple therapies recommended by the guidelines for the treatment of H. Pylori have good performance in terms of four-week eradication rate and safety outcome indicators, and due to the different resistance of antibiotics in different regional populations, rational use of drugs should be combined with local conditions. |
| format | Article |
| id | doaj-art-0765c632d298499c8d8f13c0628cdad0 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-0765c632d298499c8d8f13c0628cdad02025-08-20T02:15:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01202e031893710.1371/journal.pone.0318937Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.Jiali WeiZehao ZhengXin WangBoyi JiaMingyao SunJiayi WangQin WanMei HanYue Qiu<h4>Background</h4>Currently, quadruple therapy is unanimously recommended as the current first-line treatment option for Helicobacter pylori (H. Pylori) eradication. However, the drug composition of quadruple therapy is very complex, and the efficacy and safety between them is not clear.<h4>Aims</h4>To compare the efficacy and safety of H. Pylori eradication regimens, which were recommended by the Fifth Consensus of China, by network meta-analysis.<h4>Methods</h4>Literature databases were used to retrieve clinical randomized controlled trials of H. Pylori eradication. Network meta-analysis was performed using BUGSnet and meta package of R software, using OR values as effect size, and SUCRA was used to rank the efficacy of interventions under each outcome.<h4>Results</h4>A total of 55 studies and 130 arms were included. The NMA analysis found that the top regimen in term of eradication rate outcome was: Rabeprazole + Bismuth + Furazolidone + Tetracycline (SUCRA, 97.5). In terms of safety outcomes: Lansoprazole + Bismuth + Amoxycillin + Clarithromycin (SUCRA, 91.97).<h4>Conclusions</h4>The bismuth quadruple therapies recommended by the guidelines for the treatment of H. Pylori have good performance in terms of four-week eradication rate and safety outcome indicators, and due to the different resistance of antibiotics in different regional populations, rational use of drugs should be combined with local conditions.https://doi.org/10.1371/journal.pone.0318937 |
| spellingShingle | Jiali Wei Zehao Zheng Xin Wang Boyi Jia Mingyao Sun Jiayi Wang Qin Wan Mei Han Yue Qiu Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. PLoS ONE |
| title | Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. |
| title_full | Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. |
| title_fullStr | Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. |
| title_full_unstemmed | Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. |
| title_short | Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis. |
| title_sort | guideline based bismuth quadruple therapy for helicobacter pylori infection in china a systematic review and network meta analysis |
| url | https://doi.org/10.1371/journal.pone.0318937 |
| work_keys_str_mv | AT jialiwei guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT zehaozheng guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT xinwang guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT boyijia guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT mingyaosun guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT jiayiwang guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT qinwan guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT meihan guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis AT yueqiu guidelinebasedbismuthquadrupletherapyforhelicobacterpyloriinfectioninchinaasystematicreviewandnetworkmetaanalysis |